Literature DB >> 20514621

Conventional chromogenic heparin assays are influenced by patient's endogenous plasma Antithrombin levels.

L G Mitchell1, P Vegh.   

Abstract

OBJECTIVES: To determine, in vitro, the influence of plasma AT concentrations on heparin levels as measured by commercially available chromogenic kits.
METHODS: Purified AT was added to plasma that was immune depleted of AT at the following final concentrations: 0, 0.5, 1.0, 1.5, 2.0, 2.5 u/ml. Heparin was added to each of the AT concentrations at the following final concentrations: 0, 0.2, 0.4 u/ml. Heparin levels were then determined using 5 different Anti-Xa (n=4) or Anti-IIa (n=1) commercial kits. All kits provided purified AT to be added to the assay system.
RESULTS: When heparin was added to plasma, heparin concentrations measured were dependent on plasma concentrations of AT (p<0.001). When plasma concentrations of AT were less than 1.0 u/ml heparin concentrations were underestimated and when plasma concentrations of AT were greater than 1.0 u/ml actual heparin levels were over estimated. There was no significant difference in the findings between the various commercial Xa or IIa kits. In the absence of heparin, anticoagulant activity was detected when plasma AT concentrations were above 1.0 u/ml. There was a statistically significant correlation between plasma concentrations of AT and the amount of anticoagulant activity (p<0.001).
CONCLUSIONS: Conventional chromogenic heparin assays are influenced by endogenous plasma AT levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514621     DOI: 10.1055/s-0030-1251988

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  4 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials.

Authors:  Hugo Maas; Savion Gropper; Fenglei Huang; Joachim Stangier; Igor Tartakovsky; Martina Brueckmann; Jacqueline M L Halton; Lesley G Mitchell
Journal:  Thromb Haemost       Date:  2018-08-15       Impact factor: 5.249

3.  Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials.

Authors:  Lesley G Mitchell; Daniel Röshammar; Fenglei Huang; Manuela Albisetti; Leonardo R Brandão; Lisa Bomgaars; Elizabeth Chalmers; Jacqueline Halton; Matteo Luciani; David Joseph; Igor Tartakovsky; Savion Gropper; Martina Brueckmann
Journal:  Thromb Haemost       Date:  2022-07-31       Impact factor: 6.681

4.  Determination of Age-Dependent Reference Ranges for Coagulation Tests Performed Using Destiny Plus.

Authors:  Fatma Demet Arslan; Muhittin Serdar; Elif Merve Ari; Mustafa Onur Oztan; Sureyya Hikmet Kozcu; Huseyin Tarhan; Ozgur Cakmak; Merve Zeytinli; Hamit Yasar Ellidag
Journal:  Iran J Pediatr       Date:  2016-04-30       Impact factor: 0.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.